DK1368478T3 - A polypeptide that induces HIV neutralizing antibodies - Google Patents

A polypeptide that induces HIV neutralizing antibodies

Info

Publication number
DK1368478T3
DK1368478T3 DK02710945T DK02710945T DK1368478T3 DK 1368478 T3 DK1368478 T3 DK 1368478T3 DK 02710945 T DK02710945 T DK 02710945T DK 02710945 T DK02710945 T DK 02710945T DK 1368478 T3 DK1368478 T3 DK 1368478T3
Authority
DK
Denmark
Prior art keywords
polypeptide
neutralizing antibodies
hiv neutralizing
induces hiv
induces
Prior art date
Application number
DK02710945T
Other languages
Danish (da)
Inventor
Robert Brasseur
Michel Chevalier
Tino Krell
Regis Sodoyer
Habib Raphaelle El
Benoit Charloteaux
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0100141A external-priority patent/FR2819256B1/en
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Application granted granted Critical
Publication of DK1368478T3 publication Critical patent/DK1368478T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention concerns a polypeptide capable of forming a structure corresponding or analogous to the intermediate state of gp41 and its use in a vaccine for preventing and treating HIV-mediated infections.
DK02710945T 2001-01-05 2002-01-04 A polypeptide that induces HIV neutralizing antibodies DK1368478T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0100141A FR2819256B1 (en) 2001-01-05 2001-01-05 POLYPEPTIDE INDUCING HIV NEUTRALIZING ANTIBODIES
FR0100848 2001-01-23

Publications (1)

Publication Number Publication Date
DK1368478T3 true DK1368478T3 (en) 2006-08-28

Family

ID=26212817

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02710945T DK1368478T3 (en) 2001-01-05 2002-01-04 A polypeptide that induces HIV neutralizing antibodies

Country Status (10)

Country Link
EP (1) EP1368478B1 (en)
AT (1) ATE324450T1 (en)
AU (1) AU2002229850A1 (en)
CA (1) CA2431881C (en)
CY (1) CY1105629T1 (en)
DE (1) DE60210936T2 (en)
DK (1) DK1368478T3 (en)
ES (1) ES2260416T3 (en)
PT (1) PT1368478E (en)
WO (1) WO2002053587A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1445614A1 (en) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) A method for the in vitro assessment of the progression status of an HIV virus in an invidual
WO2005076001A2 (en) * 2004-02-06 2005-08-18 Inserm (Institut National De La Sante Et De La Recherche Medicale) A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual
ATE508139T1 (en) 2003-04-11 2011-05-15 Pasteur Institut SYNTHETIC PEPTIDE HIV VACCINE: THE CBD EPITOPE AS AN EFFICIENT IMMUNOGEN FOR THE INDUCTION OF HIV-NEUTRALIZING ANTIBODIES
WO2014020205A2 (en) * 2012-07-31 2014-02-06 Universidad De Granada Improved anti-hiv immunogens
CN108997482A (en) * 2018-08-09 2018-12-14 东莞市朋志生物科技有限公司 for detecting the synthetic peptide of HIV-1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000008043A2 (en) * 1998-08-03 2000-02-17 The University Of Montana Prevention and treatment of viral disease
EP1149115A4 (en) * 1999-01-08 2005-11-02 Panacos Pharmaceuticals Inc METHODS OF ELICITING BROADLY NEUTRALIZING ANTIBODIES TARGETING HIV-1 gp41

Also Published As

Publication number Publication date
WO2002053587A3 (en) 2003-09-25
CY1105629T1 (en) 2010-12-22
CA2431881C (en) 2011-02-22
CA2431881A1 (en) 2002-07-11
PT1368478E (en) 2006-07-31
AU2002229850A1 (en) 2002-07-16
DE60210936T2 (en) 2006-10-19
WO2002053587A2 (en) 2002-07-11
EP1368478B1 (en) 2006-04-26
EP1368478A2 (en) 2003-12-10
ATE324450T1 (en) 2006-05-15
ES2260416T3 (en) 2006-11-01
DE60210936D1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
BR0014282A (en) Vaccines
MXPA02007413A (en) Novel use.
MXPA02007478A (en) Human immunodeficiency virus vaccine.
DE60125797D1 (en) IMPFSTOFFZUSAMMESETZUNG
WO2003039470A3 (en) Polyvalent immunogen of hiv
DK1362109T3 (en) Recombinant oligomeric protein complexes with enhanced immunogenic potential
ATE458496T1 (en) HIV VACCINES AND METHODS OF APPLICATION
DK1404367T3 (en) Use of polyclonal anti-HIV goat serum as a therapeutic agent
YU68602A (en) Monoclonal antibodies to the human ldl receptor, their production and use
CY1105629T1 (en) POLYPEPTIDE INDUCING HIV NEUTRALIZING ANTIBODIES
CY1106200T1 (en) ANTIBODIES TO CASPASE-8, THEIR PREPARATION AND USE
EE200300213A (en) Use of SARP-1 for the treatment and / or prevention of scleroderma
EP1546415A4 (en) Anti-tsg101 antibodies and their uses for treatment of viral infections
DK1427441T3 (en) Composite superimmunogen for bifunctional vaccine, Tat-gp160, for use in the treatment of AIDS
TW200621800A (en) Human immunodeficiency virus vaccine
HUP0303423A2 (en) Natural antibody active against hiv virus
FR2819256B1 (en) POLYPEPTIDE INDUCING HIV NEUTRALIZING ANTIBODIES
AU2001270226A1 (en) Tolerance and chronic hepatitis c virus
FR2839721B1 (en) POLYPEPTIDE ANTIGEN INDUCING HIV NEUTRALIZING ANTIBODIES
AU2003255866A8 (en) Gp41 epitope and uses thereof for the treatment of hiv infections
UY26080A1 (en) NEW DIHYDROPYRIMIDINES
RU2001107405A (en) METHOD FOR INCREASING HUMAN STATOKINETIC STABILITY
UA38786A (en) FIBRINOLYTIC MEDICINE